Archive for May, 2014

We put up with dry, itchy skin and are constantly applying creams to try (in vain) to fight the flake - but there might be some much needed good news for us eczema sufferers.

New research suggests eczema sufferers may have less chance of developing skin cancer.

A study conducted by experts at King's College London found the immune response triggered by eczema could stop tumours forming by shedding potentially cancerous cells.

Genetically engineered mice lacking three skin proteins - known as "knock-out" mice - were used to replicate some of the skin defects found in eczema sufferers.

Cancer-causing chemicals were tested on normal mice and the knock-out mice. Researchers found the number of benign tumours per mouse was six times lower in knock-out mice.

The new study, published in eLife, suggests both types of mice were equally susceptible to getting cancer-causing mutations, but an exaggerated inflammatory reaction in knock-out mice led to enhanced shedding of potentially cancerous cells from the skin.

Professor Fiona Watt, director of the centre for stem cells and regenerative medicine at King's College London, said: "We are excited by our findings as they establish a clear link between cancer susceptibility and an allergic skin condition in our experimental model.

"They also support the view that modifying the body's immune system is an important strategy in treating cancer.

"I hope our study provides some small consolation to eczema sufferers - that this uncomfortable skin condition may actually be beneficial in some circumstances."

See more here:
Eczema Could Reduce The Risk Of Skin Cancer, Research Shows

PUBLIC RELEASE DATE:

5-May-2014

Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center

BOSTON -- Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research. Finding an effective anti-cancer medication from the pool of drugs already approved for the treatment of other medical conditions could cut a considerable amount of time and money from the process.

Now, using a novel bioinformatics approach, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that the approved antimicrobial drug pentamidine may help in the treatment of patients with advanced kidney cancer. Described online in the journal Molecular Cancer Therapeutics, the discovery reveals how linking cancer gene expression patterns with drug activity might help advance cancer care.

"The strategy of repurposing drugs that are currently being used for other indications is of significant interest to the medical community as well as the pharmaceutical and biotech industries," says senior author Towia Libermann, PhD, Director of the Genomics, Proteomics, Bioinformatics and Systems Biology Center at BIDMC and Associate Professor of Medicine at Harvard Medical School. "Our results demonstrate that bioinformatics approaches involving the analysis and matching of cancer and drug gene signatures can indeed help us identify new candidate cancer therapeutics."

Renal cell cancer consists of multiple subtypes that are likely caused by different genetic mutations. Over the years, Libermann has been working to identify new disease markers and therapeutic targets through gene expression signatures of renal cell cancer that distinguish these different cancer subtypes from each other, as well as from healthy individuals. In this new paper, he and his colleagues were looking for drugs that might be effective against clear cell renal cancer, the most common and highly malignant subtype of kidney cancer. Although patients with early stage disease can often be successfully treated through surgery, up to 30 percent of patients with renal cell cancer present with advanced stages of disease at the time of their diagnosis.

To pursue this search, they made use of the Connectivity Map (C-MAP) database, a collection of gene expression data from human cancer cells treated with hundreds of small molecule drugs.

"C-MAP uses pattern-matching algorithms to enable investigators to make connections between drugs, genes and diseases through common, but inverse, changes in gene expression," says Libermann. "It provided us with an exciting opportunity to use our renal cell cancer gene signatures and a new bioinformatics strategy to match kidney cancer gene expression profiles from individual patients with gene expression changes inducted by various commonly used drugs."

After identifying drugs that may reverse the gene expression changes associated with renal cell cancer, the investigators used assays to measure the effect of the selected drugs on cells. This led to the identification of a small number of FDA-approved drugs that induced cell death in multiple kidney cancer cell lines. The investigators then tested three of these drugs in an animal model of renal cell cancer and demonstrated that the antimicrobial agent pentamidine (primarily used for the treatment of pneumonia) reduced tumor growth and enhanced survival. Gene expression experiments using microarrays also identified the genes in renal cell cancer that were counteracted by pentamidine.

Read the original post:
Bioinformatics approach helps researchers find new uses for old drug

d27m - genetic engineering (omd cover) 2014
genetic engineering by d27m. 2014. http://www.d27m.fr.mu.

By: allankardec17

Go here to see the original:
d27m - genetic engineering (omd cover) 2014 - Video

Minecraft- Genetic Engineering Ranch Tour
This is Dr. Mephesto #39;s Lab.

By: SouthParkGamer45

See the rest here:
Minecraft- Genetic Engineering Ranch Tour - Video

Process - Genetic Engineering and Biotechnology

By: Andrew Haaheim

View original post here:
Process - Genetic Engineering and Biotechnology - Video

PUBLIC RELEASE DATE:

5-May-2014

Contact: Sid Dinsay sid.dinsay@mountsinai.org 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine

In the largest family study on autism spectrum disorder (ASD) to date, researchers from the Icahn School of Medicine at Mount Sinai, along with a research team from the Karolinska Institutet in Stockholm Sweden and King's College in London found that individual risk of ASD and autistic disorder increased with greater genetic relatedness in families that is, persons with a sibling, half-sibling or cousin diagnosed with autism have an increased likelihood of developing ASD themselves. Furthermore, the research findings showed that "environmental" factors unique to the individual (birth complications, maternal infections, etc.) were more of a determinant for ASD than previously believed.

The population-based, longitudinal study, titled "The Familial Risk of Autism," was led by Abraham Reichenberg, PhD, Professor of Psychiatry and Preventive Medicine at the Icahn School of Medicine at Mount Sinai, and was first published online in the Journal of the American Medical Association.

"The findings from this extensive, prospective study will help improve how we counsel families with children who suffer from ASD and autistic disorder," said Dr. Reichenberg. "Currently, ASD affects nearly one percent of all children born in the United States. This study tells us that while we continue to study the genetic risk factors associated with ASD, we should find what environmental factors may play a role as well."

ASD is defined as impairment in social interaction and communication and the presence of restricted interests and repetitive behaviors; in the U.S., approximately one percent of the population is believed to have ASD. For purposes of this study, ASD included the definition for Asperger syndrome.

The study cohort comprised more than two million Swedish children born in 1982 through 2006, and included more than 1.6 million unique families. The breadth of this study allowed researchers the opportunity to examine a large spectrum of relatedness, including monozygotic (identical) and dizygotic (fraternal) twins; full siblings; maternal and paternal half siblings; and cousins. Single-child families were excluded from this study.

Researchers studied the relative recurrence risk, or RRR, for autism spectrum disorder and autistic disorder in these families and used it to determine heritability. Recurrence risk expresses the risk of having another affected family member in an already-affected family that is, the likelihood of a person in a family to be diagnosed with ASD if they have a sibling or cousin with autism spectrum disorder. RRR measures this recurrence in relation to disease in families without any affected members.

In calculating RRR for the different genetic relations, the researchers found that the closer the genetic relatedness, the greater the risk a sibling or cousin would also be diagnosed. Monozygotic twins had the highest adjusted RRR for ASD (estimated to be 153 times more likely to develop ASD); followed by full siblings (10.3 times), dizygotic twins (8.2), maternal half-siblings (3.3), paternal half-siblings (2.9) and cousins (2.0). Similar, if slightly higher, adjusted RRRs are found for autistic disorder: monozygotic twins (116.8), dizygotic twins (16.9), full siblings (14.6), maternal half-siblings (4.3), paternal half-siblings (2.9), and cousins (2.3).

See original here:
Genetic, environmental influences equally important risk for autism spectrum disorder

Contact Information

Available for logged-in reporters only

Newswise In the largest family study on autism spectrum disorder (ASD) to date, researchers from the Icahn School of Medicine at Mount Sinai, along with a research team from the Karolinska Institutet in Stockholm Sweden and Kings College in London found that individual risk of ASD and autistic disorder increased with greater genetic relatedness in families that is, persons with a sibling, half-sibling or cousin diagnosed with autism have an increased likelihood of developing ASD themselves. Furthermore, the research findings showed that environmental factors unique to the individual (birth complications, maternal infections, etc.) were more of a determinant for ASD than previously believed.

The population-based, longitudinal study, titled "The Familial Risk of Autism," was led by Abraham Reichenberg, PhD, Professor of Psychiatry and Preventive Medicine at the Icahn School of Medicine at Mount Sinai, and was first published online in the Journal of the American Medical Association.

The findings from this extensive, prospective study will help improve how we counsel families with children who suffer from ASD and autistic disorder, said Dr. Reichenberg. Currently, ASD affects nearly one percent of all children born in the United States. This study tells us that while we continue to study the genetic risk factors associated with ASD, we should find what environmental factors may play a role as well. ASD is defined as impairment in social interaction and communication and the presence of restricted interests and repetitive behaviors; in the U.S., approximately one percent of the population is believed to have ASD. For purposes of this study, ASD included the definition for Asperger syndrome.

The study cohort comprised more than two million Swedish children born in 1982 through 2006, and included more than 1.6 million unique families. The breadth of this study allowed researchers the opportunity to examine a large spectrum of relatedness, including monozygotic (identical) and dizygotic (fraternal) twins; full siblings; maternal and paternal half siblings; and cousins. Single-child families were excluded from this study. Researchers studied the relative recurrence risk, or RRR, for autism spectrum disorder and autistic disorder in these families and used it to determine heritability. Recurrence risk expresses the risk of having another affected family member in an already-affected family that is, the likelihood of a person in a family to be diagnosed with ASD if they have a sibling or cousin with autism spectrum disorder. RRR measures this recurrence in relation to disease in families without any affected members.

In calculating RRR for the different genetic relations, the researchers found that the closer the genetic relatedness, the greater the risk a sibling or cousin would also be diagnosed. Monozygotic twins had the highest adjusted RRR for ASD (estimated to be 153 times more likely to develop ASD); followed by full siblings (10.3 times), dizygotic twins (8.2), maternal half-siblings (3.3), paternal half-siblings (2.9) and cousins (2.0). Similar, if slightly higher, adjusted RRRs are found for autistic disorder: monozygotic twins (116.8), dizygotic twins (16.9), full siblings (14.6), maternal half-siblings (4.3), paternal half-siblings (2.9), and cousins (2.3).

Participants were followed for 20 years or until 2009, whichever came first. (Regular medical and developmental examinations are required for Swedish children as infants and throughout preschool.) At four years of age, a mandatory developmental assessment is conducted. From that assessment, children with suspected developmental disorders are referred for additional assessment. These assessments ensured completeness of data for the study.

This study held several advantages over previous studies, which may account for differences in research findings. The large sample size, established using data from multiple Swedish national registries, provided researchers with an unbiased population-based sample. Additionally, the length of follow-up time in this study increased the reliability of the finding results. This study was also one of the first to be able to accurately calculate RRR, by including twice as many cases of ASD and more detailed family data, including monozygotic and dizygotic twins and cousins, than previous studies.

This study was supported, in part, by grants from the National Institutes of Health: Grant HD073978 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Environmental Health Sciences, and National Institute of Neurological Disorders and Stroke; and Grant MH097849 from the National Institute of Mental Health; and by the Beatrice and Samuel A. Seaver Foundation.

Read more here:
Genetic and Environmental Influences Are Equally Important Risk Factors for Autism Spectrum Disorder

Minecraft Tutorials - Advanced Genetics - Man Plus
Part two of my Minecraft tutorial series for Advanced Genetics. In this video you will find out how to make yourself super human in any mod pack that include...

By: IDEDonline

Read this article:
Minecraft Tutorials - Advanced Genetics - Man Plus - Video

University of California, Irvine - Department of Microbiology Molecular Genetics
Researchers in the Microbiology and Molecular Genetics department work on several different aspects of digestive disorders. These include the development of more sensitive DNA sequencing approaches...

By: WebsEdgeHealth

Read more:
University of California, Irvine - Department of Microbiology & Molecular Genetics - Video

Revision: Genetics
Download the Show Notes: http://learn.mindset.co.za/learn/sites/files/LXL2014/LXL_Gr12LifeSciences_12_Revision_Genetics_30Apr2014.pdf In this Gr 12 Life Sciences show we take another look...

By: MindsetLearn

More:
Revision: Genetics - Video

Gene Therapy using SMaRT

By: chee ching Ng

View original post here:
Gene Therapy using SMaRT - Video

SCID gene therapy class

By: sw tue

Read the original:
SCID gene therapy class - Video

Washington, DC (PRWEB) May 05, 2014

There will be a Media Event in Washington, DC, on Wednesday, May 21, 2014, from 10:45 am 12:15 pm in Wilson A of the Marriott Wardman Park Hotel, which is sponsored by the American Society of Gene & Cell Therapy (ASGCT).

The event will profile exciting clinical trial results in patients suffering from serious and often fatal diseases such as human immunodeficiency virus (HIV), Inherited Immunodeficiencies, Hemophilia B, and complications from Thrombosis. All registered media will have the opportunity for personal, one-on-one questions with academic and industry leaders in the field, including:

Dr. Bruce L. Levine of the University of Pennsylvania is developing a gene and cell therapy strategy to achieve a functional cure for HIV infection by genome editing of cells, and results from the first-in-human trial of this novel treatment strategy will be presented.

Professor Adrian Thrasher of the University College of Londons Institute of Child Health will discuss the impressive results of recent advances in gene therapy technology to treat inherited immunodeficiencies in patients, many of whom are children.

Researchers at St. Jude Children's Research Hospital have successfully treated Hemophilia patients with gene therapy that led to their disease-free living for several years. Dr. Andrew Davidoff will provide the latest update on these exciting clinical results.

Thrombosis, or the formation of blood clots inside a blood vessel, remains the major cause of death and disability in the western world. Dr. Bruce Sullenger of Duke University Medical Center will describe the recent development of gene and cell therapy strategies to control thrombosis that is currently in a Phase 3 clinical trial.

The media event will take place in Wilson A in the Marriott Wardman Park Hotel.

Members of the media are welcome to conduct individual interviews with each speaker following the presentation, and will receive complimentary full-access registration to the ASGCT 17th Annual Meeting. Representatives who wish to attend may contact ASGCT directly at 414.278.1341 or mdean(at)asgct(dot)org.

The American Society of Gene & Cell Therapy (ASGCT) is a professional nonprofit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. For more information on ASGCT, visit its website, http://www.asgct.org.

See the rest here:
Gene and Cell Therapy for Thrombosis, AIDS and Inherited Disorders

Contact Information

Available for logged-in reporters only

Newswise Orlando, Fla. In two separate studies, vision scientists have developed healthy genes to prevent blinding diseases that stem from genetic defects. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando, Fla.

In a clinical trial to treat choroideremia, a rare disease that causes progressive and irreversible blindness, scientists developed a virus that can replace the missing gene (that causes the disease) in the cells at the back of the eye. Six months after the virus was injected into patients, findings showed that some patients experienced improved vision.

Abstract Title: Improved visual function in patients with choroideremia undergoing subretinal gene therapy Presentation Start/End Time: Sunday, May 4, 3:15 3:30pm Location: S 320AB Session Number: 147

In a separate study, researchers developed a gene therapy to stop the progression of a form of retinitis pigmentosa, an inherited disease transmitted from mothers to sons. Two years after the therapy was used to treat dogs at an early stage of the disease, the treatment remained effective. Further use of the technique in dogs with mid and late stages of the disease also resulted in a positive response to the intervention.

Abstract Title: RPGR gene augmentation delivered at early, mid and late stage disease in a canine model of XLRP rescues photoreceptor structure and function Presentation Start/End Time: Tuesday, May 6, 11am 12:45pm Location: Exhibit/Poster Hall SA Session Number: 342 # # #

The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include some 11,500 eye and vision researchers from over 70 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication.

Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.

Visit link:
Gene Therapy Used to Preserve Sight in Patients

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research. Finding an effective anti-cancer medication from the pool of drugs already approved for the treatment of other medical conditions could cut a considerable amount of time and money from the process.

Now, using a novel bioinformatics approach, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that the approved antimicrobial drug pentamidine may help in the treatment of patients with advanced kidney cancer. Described online in the journal Molecular Cancer Therapeutics, the discovery reveals how linking cancer gene expression patterns with drug activity might help advance cancer care.

"The strategy of repurposing drugs that are currently being used for other indications is of significant interest to the medical community as well as the pharmaceutical and biotech industries," says senior author Towia Libermann, PhD, Director of the Genomics, Proteomics, Bioinformatics and Systems Biology Center at BIDMC and Associate Professor of Medicine at Harvard Medical School. "Our results demonstrate that bioinformatics approaches involving the analysis and matching of cancer and drug gene signatures can indeed help us identify new candidate cancer therapeutics."

Renal cell cancer consists of multiple subtypes that are likely caused by different genetic mutations. Over the years, Libermann has been working to identify new disease markers and therapeutic targets through gene expression signatures of renal cell cancer that distinguish these different cancer subtypes from each other, as well as from healthy individuals. In this new paper, he and his colleagues were looking for drugs that might be effective against clear cell renal cancer, the most common and highly malignant subtype of kidney cancer. Although patients with early stage disease can often be successfully treated through surgery, up to 30 percent of patients with renal cell cancer present with advanced stages of disease at the time of their diagnosis.

To pursue this search, they made use of the Connectivity Map (C-MAP) database (http://www.broadinstitute.org/cmap), a collection of gene expression data from human cancer cells treated with hundreds of small molecule drugs.

"C-MAP uses pattern-matching algorithms to enable investigators to make connections between drugs, genes and diseases through common, but inverse, changes in gene expression," says Libermann. "It provided us with an exciting opportunity to use our renal cell cancer gene signatures and a new bioinformatics strategy to match kidney cancer gene expression profiles from individual patients with gene expression changes inducted by various commonly used drugs."

After identifying drugs that may reverse the gene expression changes associated with renal cell cancer, the investigators used assays to measure the effect of the selected drugs on cells. This led to the identification of a small number of FDA-approved drugs that induced cell death in multiple kidney cancer cell lines. The investigators then tested three of these drugs in an animal model of renal cell cancer and demonstrated that the antimicrobial agent pentamidine (primarily used for the treatment of pneumonia) reduced tumor growth and enhanced survival. Gene expression experiments using microarrays also identified the genes in renal cell cancer that were counteracted by pentamidine.

"One of the main challenges in treating cancer is the identification of the right drug for the right individual," explains first author Luiz Fernando Zerbini, PhD, of the International Center for Genetic Engineering and Biotechnology in Cape Town, South Africa, adding that this bioinformatics approach could be a particularly valuable lower-cost model in developing countries.

The authors say their next step will be to evaluate the potential of pentamidine in combination with the current standard-of-care therapies to treat kidney cancer. "Since the drugs we are evaluating are already FDA-approved, successful studies in preclinical animal models may enable us to rapidly move these drugs into clinical trials," adds Libermann.

Story Source:

Read this article:
Bioinformatics approach helps researchers find new use for old drug

Personalized Medicine 2.0 Webinar Series - Integrating Key Learnings Across the Organization
This webinar, the second in Diaceutics #39; series on Personalized Medicine (PM), focused on PM education across the pharmaceutical company from the R D team t...

By: DiaceuticsLabceutics

See the rest here:
Personalized Medicine 2.0 Webinar Series - Integrating Key Learnings Across the Organization - Video

Ron G, C4 SCI, walking at Project Walk Atlanta
C4 SCI, tetraplegic, after months of therapy at Project Walk Atlanta, and surely after being turned away from the Shepherd Center, we have progressed him to walking.

By: ProjectWalkAtlanta Spinal Cord Injury Recovery

The rest is here:
Ron G, C4 SCI, walking at Project Walk Atlanta - Video

Amanda #39;s New Life - Promo
Watch the full episode on AttitudeLive. http://attitudelive.com/documentary/amandas-new-life Amanda Lowry had just celebrated her master #39;s degree and birth of her second daughter when a surfing...

By: AttitudeTV

Originally posted here:
Amanda's New Life - Promo - Video

Santa Ana Personal Injury Attorney
If you have been seriously injured by the reckless act of another, you have a personal injury claim. At DiMarco Araujo and Montevideo, our attorneys have been helping injured victims of accidents...

By: Di Marco Araujo Montevideo

Read more:
Santa Ana Personal Injury Attorney - Video

Chair-Leader #39;s 2013
CEO Doug Newson of Charlottetown Airport Authority talks about being a Chair-Leader in 2013.

By: Spinal Cord Injury- PEI

See the rest here:
Chair-Leader's 2013 - Video

Pediatric Cardiologist Dr. Abraham Rudolph on Regenerative Medicine
Nationwide Children #39;s was honored to host world-renowned pediatric cardiologist Dr. Abraham Rudolph at our hospital. Hear his comments on future opportunitie...

By: NationwideChildrens

See the original post here:
Pediatric Cardiologist Dr. Abraham Rudolph on Regenerative Medicine - Video

Scottsdale, Arizona (PRWEB) May 05, 2014

Top Phoenix and Scottsdale foot and ankle doctors at Valley Foot Surgeons are now offering stem cell procedures for the nonoperative treatment of Achilles tendonitis and tears. The regenerative medicine procedures are typically able to provide exceptional pain relief while allowing patients the ability to avoid surgery. Call (480) 420-3499 for more information and scheduling about the foot and ankle stem cell procedures.

To date, the lead foot and ankle doctor at Valley Foot Surgeons, Dr. Richard Jacoby, has performed close to 100 regenerative medicine procedures. Typically, these are administered for a variety of conditions such as diabetic ulcers, foot and ankle arthritis, plantar fasciitis, and Achilles injuries.

Conditions with the Achilles tendon may include pain due to chronic tendonitis or tears from degeneration. This may occur during a sporting activity, traumatic event, or simply as part of an individual's tendon weakening after taking quinolone antibiotics.

The stem cell procedures are performed as an outpatient, with the injections consisting of amniotic derived stem cells. The material is harvested from consenting donors after scheduled c-section procedures, with no fetal tissue at all being used.

The material is exceptionally rich in stem cells, growth factors, hyaluronic acid, and more. This can dramatically improve pain relief and healing, which is very different from how steroid medications work.

All too often, traditional treatments for Achilles tendonitis and tears fail to provide relief. This may lead to potentially risky surgery, where complications may lead to continued disability.

With the stem cells for Achilles tears and tendonitis, patients go through an outpatient procedure that is low risk and offers the potential for avoiding the risks of surgery while speeding up recovery.

Dr. Jacoby at Valley Foot Surgeons has been a four time Phoenix Top Doc Winner and sees patients out of two offices in the Valley. For the top stem cell treatment for achilles conditions, diabetic wounds, foot and ankle arthritis and more, call (480) 420-3499.

Here is the original post:
Valley Foot Surgeons Now Offering Stem Cell Procedures for Achilles Tendonitis and Tears for Pain Relief and Helping ...

Hip and knee arthritis 5 months after stem cell therapy by Dr Harry Adelson
Richard describes his outcome 5 months after stem cell therapy by Dr Harry Adelson for his hip and knee arthritis http://www.docereclinics.com.

By: Harry Adelson, N.D.

See original here:
Hip and knee arthritis 5 months after stem cell therapy by Dr Harry Adelson - Video

by Andrea Lutz

KTVB.COM

Posted on May 4, 2014 at 9:41 PM

Updated yesterday at 11:04 PM

BOISE -- Modern medicine and early detection are helping women in the fight against breast cancer, but recently a decision in our nation's highest court has made it easier to afford the cost of genetic cancer testing.

The Saint Alphonsus Breast Cancer Center in Boise reports that one in 500 breast cancer cases women have what's called the BRCA gene mutation.

Saint Als Breast Surgeon Elizabeth Prier says knowledge of the BRCA gene has been around for the last decade, and identifying at-risk women has intesified in the last five years.

A lot of women with BRCA1 will end up with breast cancer in their 30s sometimes in their late 20s, said Dr. Prier.

That means women end up starting their fight with the disease earlier.

Annie Pierce, a wife and mother of two, ended her battle with breast cancer before it even started.

Read the original here:
Breast cancer test made famous by Angelina Jolie now more affordable

The Sims 3: Perfect Genetics Challenge- {Part 1} Meet Khaleesi.
Read Me. *Warning* The first couple of episodes of this LP were recorded all at once, and the audio got kind of weird there for a bit, but still new at this so please don #39;t...

By: Moar Sims

Read this article:
The Sims 3: Perfect Genetics Challenge- {Part 1} Meet Khaleesi. - Video